Drug intelligence / Profile preview

cannabigerol

Development stage
Phase 3
Lead developer
Willow Biosciences
Modality
Small Molecules
Administration
Oral, Sublingual, Topical, Inhalation, Ophthalmic, Transdermal
01

Overview

Cannabigerol (CBG) is a non-psychoactive cannabinoid and a minor constituent of the cannabis plant. It is the decarboxylated form of cannabigerolic acid (CBGA), which serves as the precursor molecule for other major cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). CBG acts as a weak partial agonist at cannabinoid CB1 and CB2 receptors but has much higher potency as an agonist at alpha-2 adrenergic receptors, an antagonist at serotonin 5-HT1A receptors, and an antagonist at transient receptor potential channel TRPM8. These diverse mechanisms contribute to its pharmacological profile, including potential anti-inflammatory, analgesic, anxiolytic, hypotensive, antioxidant effects, and possible applications in metabolic syndrome and cardiovascular diseases. Recent clinical research suggests that oral administration of CBG can reduce anxiety without causing intoxication[1][3][4][5].

Other names
cannabigerolCBG
02

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)ADRA2A (α2A)CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on cannabigerol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabigerol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call